The FDA placed it in 503A Category 2 ("may present significant safety risks") in 2023, effectively barring compounding pharmacies from using it, then removed it from that category in April 2026 after nominators withdrew their submission, without adding it to the approved Category 1 compounding list
COA must address both compounds + ratio
If nausea remains severe at this point, discuss with your provider before advancing doses
This is a decision you and your doctor will make
Remove each patch from its liner and press firmly onto the skin
At its nanomolar biological activity threshold, meaningful fibroblast stimulation is achievable at the doses in the blend Effects and Benefits Localised tissue repair from BPC-157 particularly relevant near skin treatment sites or scarring Systemic anti-inflammatory and cell migration support from TB-500 Collagen and elastin synthesis via GHK-Cu's TGF- activation the primary driver of improved skin density and texture GHK-Cu's documented 4,000+ gene modulation includes antioxidant, repair and anti-inflammatory gene expression shifts No suppression of natural testosterone no PCT required Dosage and Administration Given the blend's localised (BPC-157) and systemic (TB-500, GHK-Cu) components, injection site has a moderate influence injecting near an area of skin concern takes advantage of BPC-157's localised mechanism, while TB-500 and GHK-Cu work systemically regardless